InvestorsHub Logo

jimmy667

10/13/17 12:23 AM

#124403 RE: falconer66a #124397

Will Insurance Companies and Medicare reimburse for A2-73?
Having not spent a Billion Dollars to run trials like BP likes to do for expensive biologics. ( manufactured in lab donor animals and other expensive low volume manufacturing)
A2-73 as a chemical compound should be an easy to manufacture in large quantities for a relative low cost.
If it is of benefit it will be a low-cost drug therefore widely used. Cost should not be a limiting factor for widespread availability to most patients that would benefit.

georgejjl

12/28/19 3:33 PM

#226991 RE: falconer66a #124397

Falconer, I agree 100%.

There is every good reason to believe that early, even prophylactic administration of Anavex 2-73 will yield symptomatic relief greater than seen in the Phase 3 clinical data. Those data will have been taken from patients with well-developed, rather advanced Alzheimer’s symptomotology. Ethically and practically, physicians won’t be waiting to prescribe Anavex 2-73 only to those with advanced symptoms. They will be writing prescripts at the earliest signs of any geriatric dementia — with a consequently greater likelihood of profound relief. Early detection; early treatment. No reason to limit treatment to populations used in the clinical trial. Consequently, results will be better than the Phase 2 and Phase 3 data. Early treatment will be better treatment. Amyloid plaques and tau tangles will be much smaller; far more amenable for successful Anavex treatment.



Good luck and GOD bless,